WAYRILZ (Rilzabrutinib) Patent Expiration, LOE Window & CMS Spending

WAYRILZ (Rilzabrutinib) by Sanofi: FDA Orange Book core substance LOE 2041-02-20, 0 AB generics, $0 2024 CMS Part D & Medicaid spend, and $17,500 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorSanofi
FDA Application & PathwayN219685 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2041-02-20
Last Listed Patent or Exclusivity Date2041-02-20
Orange Book Patents (*PED Extensions)7 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$0
2024 Medicare Part D Spend$0
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($17,500 intro WAC)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Sanofi across sibling Meru public-data platforms.